Drugs / AGI-101H
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00716495 | Jun 2008 → Dec 2009 | melanoma | AGIRx Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGI-101H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00716495 ↗ |
| Modality | Vaccine | “whole cell, allogeneic melanoma vaccine” NCT00716495 ↗ |
| Route | Subcutaneous | “Administration: Subcutaneous (s.c.)” NCT00716495 ↗ |